197 related articles for article (PubMed ID: 34673012)
1. Impact of alternative splicing on mechanisms of resistance to anticancer drugs.
Reviejo M; Soto M; Lozano E; Asensio M; Martínez-Augustin O; Sánchez de Medina F; Marin JJG
Biochem Pharmacol; 2021 Nov; 193():114810. PubMed ID: 34673012
[TBL] [Abstract][Full Text] [Related]
2. The role of alternative splicing in cancer: From oncogenesis to drug resistance.
Sciarrillo R; Wojtuszkiewicz A; Assaraf YG; Jansen G; Kaspers GJL; Giovannetti E; Cloos J
Drug Resist Updat; 2020 Dec; 53():100728. PubMed ID: 33070093
[TBL] [Abstract][Full Text] [Related]
3. Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach.
Taylor S; Spugnini EP; Assaraf YG; Azzarito T; Rauch C; Fais S
Drug Resist Updat; 2015 Nov; 23():69-78. PubMed ID: 26341193
[TBL] [Abstract][Full Text] [Related]
4. Impact of Alternative Splicing Variants on Liver Cancer Biology.
Marin JJG; Reviejo M; Soto M; Lozano E; Asensio M; Ortiz-Rivero S; Berasain C; Avila MA; Herraez E
Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008179
[TBL] [Abstract][Full Text] [Related]
5. Pre-mRNA splicing in cancer: the relevance in oncogenesis, treatment and drug resistance.
Wojtuszkiewicz A; Assaraf YG; Maas MJ; Kaspers GJ; Jansen G; Cloos J
Expert Opin Drug Metab Toxicol; 2015 May; 11(5):673-89. PubMed ID: 25495223
[TBL] [Abstract][Full Text] [Related]
6. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
7. Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs.
Marin JJ; Briz O; Monte MJ; Blazquez AG; Macias RI
Curr Cancer Drug Targets; 2012 May; 12(4):402-38. PubMed ID: 22229248
[TBL] [Abstract][Full Text] [Related]
8. Inside the biochemical pathways of thymidylate synthase perturbed by anticancer drugs: Novel strategies to overcome cancer chemoresistance.
Taddia L; D'Arca D; Ferrari S; Marraccini C; Severi L; Ponterini G; Assaraf YG; Marverti G; Costi MP
Drug Resist Updat; 2015 Nov; 23():20-54. PubMed ID: 26690339
[TBL] [Abstract][Full Text] [Related]
9. Alternative RNA Splicing-The Trojan Horse of Cancer Cells in Chemotherapy.
Mehterov N; Kazakova M; Sbirkov Y; Vladimirov B; Belev N; Yaneva G; Todorova K; Hayrabedyan S; Sarafian V
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356101
[TBL] [Abstract][Full Text] [Related]
10. Cancer cells acquire resistance to anticancer drugs: an update.
Lu HP; Chao CC
Biomed J; 2012; 35(6):464-72. PubMed ID: 23442359
[TBL] [Abstract][Full Text] [Related]
11. The multi-factorial nature of clinical multidrug resistance in cancer.
Assaraf YG; Brozovic A; Gonçalves AC; Jurkovicova D; Linē A; Machuqueiro M; Saponara S; Sarmento-Ribeiro AB; Xavier CPR; Vasconcelos MH
Drug Resist Updat; 2019 Sep; 46():100645. PubMed ID: 31585396
[TBL] [Abstract][Full Text] [Related]
12. Regulation of chemoresistance via alternative messenger RNA splicing.
Eblen ST
Biochem Pharmacol; 2012 Apr; 83(8):1063-72. PubMed ID: 22248731
[TBL] [Abstract][Full Text] [Related]
13. Modulation of alternative splicing by anticancer drugs.
Rehman SU; Husain MA; Sarwar T; Ishqi HM; Tabish M
Wiley Interdiscip Rev RNA; 2015; 6(4):369-79. PubMed ID: 25914287
[TBL] [Abstract][Full Text] [Related]
14. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
[TBL] [Abstract][Full Text] [Related]
15. Drug resistance and apoptosis in cancer treatment: development of new apoptosis-inducing agents active in drug resistant malignancies.
Tolomeo M; Simoni D
Curr Med Chem Anticancer Agents; 2002 May; 2(3):387-401. PubMed ID: 12678739
[TBL] [Abstract][Full Text] [Related]
16. Aberrant splicing, hyaluronan synthases and intracellular hyaluronan as drivers of oncogenesis and potential drug targets.
Adamia S; Pilarski PM; Belch AR; Pilarski LM
Curr Cancer Drug Targets; 2013 May; 13(4):347-61. PubMed ID: 23517594
[TBL] [Abstract][Full Text] [Related]
17. Cancer-Associated Perturbations in Alternative Pre-messenger RNA Splicing.
Shkreta L; Bell B; Revil T; Venables JP; Prinos P; Elela SA; Chabot B
Cancer Treat Res; 2013; 158():41-94. PubMed ID: 24222354
[TBL] [Abstract][Full Text] [Related]
18. Surmounting cancer drug resistance: New insights from the perspective of N
Li B; Jiang J; Assaraf YG; Xiao H; Chen ZS; Huang C
Drug Resist Updat; 2020 Dec; 53():100720. PubMed ID: 32892147
[TBL] [Abstract][Full Text] [Related]
19. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
20. mRNA splicing variants: exploiting modularity to outwit cancer therapy.
Dehm SM
Cancer Res; 2013 Sep; 73(17):5309-14. PubMed ID: 23970479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
